Subtopic Deep Dive

← Protein Interaction Studies and Fluorescence Analysis

Plasma Protein Binding Drug Development
Research Guide

What is Plasma Protein Binding Drug Development?

Plasma protein binding (PPB) in drug development studies the interaction of drugs with plasma proteins like human serum albumin (HSA) to predict pharmacokinetics, distribution, and clearance for optimizing therapeutic efficacy.

PPB primarily involves HSA, which binds diverse ligands at multiple sites, influencing drug bioavailability and half-life (Fasano et al., 2005, 1051 citations). Crystallographic studies reveal specific binding modes for drugs like warfarin in HSA sites I and II (Petitpas et al., 2001, 806 citations). Analytical tools assess binding affinity to guide ADME optimization (Vuignier et al., 2010, 378 citations).

Curated Papers

Key Challenges

Why It Matters

High PPB reduces free drug fraction available for tissue distribution, impacting efficacy and requiring dose adjustments in drug development (Fanali et al., 2011, 1817 citations). Understanding HSA binding sites via crystallography enables prediction of drug displacement interactions, minimizing toxicity risks (Bhattacharya et al., 2000, 891 citations; Petitpas et al., 2001). In nanoparticle drug delivery, protein corona formation alters pharmacokinetics, as shown in polymeric systems (Bertrand et al., 2017, 644 citations), guiding formulations for better oral bioavailability.

Key Research Challenges

Predicting Binding Affinity Accurately

Developing models to forecast drug-HSA binding strength remains challenging due to multiple binding sites and allosteric effects (Kragh-Hansen et al., 2002, 873 citations). Experimental methods like equilibrium dialysis vary in precision across drug classes (Vuignier et al., 2010). Computational simulations struggle with dynamic plasma conditions.

Quantifying Protein Corona Effects

In vivo protein corona on drug nanoparticles complicates PPB predictions, altering clearance rates (Bertrand et al., 2017, 644 citations). Distinguishing HSA-specific binding from other plasma proteins requires advanced separation techniques. Reproducibility across species hampers preclinical translation.

Optimizing Free Fraction for ADME

Balancing PPB to achieve optimal free drug levels for efficacy without excessive clearance is difficult (Fasano et al., 2005). Drug-drug interactions via site competition, like warfarin displacement, pose clinical risks (Petitpas et al., 2001). High-throughput screening methods lag behind structural insights (Fanali et al., 2011).

Essential Papers

Human serum albumin: From bench to bedside

Gabriella Fanali, Alessandra di Masi, Viviana Trezza et al. · 2011 · Molecular Aspects of Medicine · 1.8K citations

The extraordinary ligand binding properties of human serum albumin

Mauro Fasano, Stephen Curry, Enzo Terreno et al. · 2005 · IUBMB Life · 1.1K citations

Human serum albumin (HSA), the most prominent protein in plasma, binds different classes of ligands at multiple sites. HSA provides a depot for many compounds, affects pharmacokinetics of many drug...

Albumin

Gregory J. Quinlan, Greg S. Martin, Timothy W. Evans · 2005 · Hepatology · 950 citations

Human serum albumin (HSA) is an abundant multifunctional non-glycosylated, negatively charged plasma protein, with ascribed ligand-binding and transport properties, antioxidant functions, and enzym...

Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin 1 1Edited by R. Huber

Ananyo A. Bhattacharya, Tim Grüne, Stephen Curry · 2000 · Journal of Molecular Biology · 891 citations

Practical Aspects of the Ligand-Binding and Enzymatic Properties of Human Serum Albumin.

Ulrich Kragh‐Hansen, Victor Tuan Giam Chuang, Masaki Otagiri · 2002 · Biological and Pharmaceutical Bulletin · 873 citations

Recent work with approaches like recombinant mutants and X-ray crystallography has given much new information about the ligand-binding properties of human serum albumin (HSA). The information incre...

Crystal Structure Analysis of Warfarin Binding to Human Serum Albumin

I. Petitpas, Ananyo A. Bhattacharya, Sue Twine et al. · 2001 · Journal of Biological Chemistry · 806 citations

Human serum albumin (HSA) is an abundant transport protein found in plasma that binds a wide variety of drugs in two primary binding sites (I and II) and can have a significant impact on their phar...

Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics

Nicolas Bertrand, P. Grenier, Morteza Mahmoudi et al. · 2017 · Nature Communications · 644 citations

Reading Guide

Foundational Papers

Start with Fanali et al. (2011, 1817 citations) for HSA overview from structure to bedside applications; Fasano et al. (2005, 1051 citations) for ligand binding mechanisms; Petitpas et al. (2001) for drug-specific crystallography like warfarin.

Recent Advances

Study Bertrand et al. (2017, 644 citations) for protein corona in nanoparticles; Merlot et al. (2014, 617 citations) for albumin in targeted therapy.

Core Methods

Core techniques: X-ray crystallography (Bhattacharya et al., 2000; Petitpas et al., 2001), recombinant mutants and binding assays (Kragh-Hansen et al., 2002), analytical tools like chromatography (Vuignier et al., 2010).

How PapersFlow Helps You Research Plasma Protein Binding Drug Development

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph on 'Human serum albumin: From bench to bedside' (Fanali et al., 2011) to map 1817 citing works, revealing PPB-drug interaction clusters; exaSearch uncovers fluorescence-based binding assays; findSimilarPapers links to Curry's crystallographic studies.

Analyze & Verify

Analysis Agent applies readPaperContent to extract binding constants from Fasano et al. (2005), verifies claims with CoVe against Quinlan et al. (2005), and runs PythonAnalysis for statistical correlation of citation impacts on PPB models using NumPy/pandas; GRADE grading scores evidence strength for HSA site predictions.

Synthesize & Write

Synthesis Agent detects gaps in PPB prediction for nanoparticles (post-Bertrand 2017), flags contradictions in binding site classifications; Writing Agent uses latexEditText for methods sections, latexSyncCitations for 10+ references, latexCompile for full reviews, and exportMermaid for HSA binding site diagrams.

Use Cases

"Extract and plot PPB dissociation constants Kd from HSA-drug papers using Python."

Research Agent → searchPapers('HSA Kd values') → Analysis Agent → readPaperContent(Fasano 2005) → runPythonAnalysis(pandas plot Kd vs drug class) → matplotlib figure of binding affinities.

"Write LaTeX review on warfarin-HSA crystallography with citations."

Research Agent → citationGraph(Petitpas 2001) → Synthesis → gap detection → Writing Agent → latexEditText(structure review) → latexSyncCitations(10 papers) → latexCompile(PDF with figures).

"Find GitHub code for PPB simulation models from recent papers."

Research Agent → searchPapers('plasma protein binding simulation') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(analyze Python scripts for HSA docking).

Automated Workflows

Deep Research workflow conducts systematic review of 50+ PPB papers: searchPapers(HSA drug binding) → citationGraph → DeepScan(7-step verify) → GRADE report on ADME impacts. Theorizer generates hypotheses on corona effects from Bertrand (2017) via literature synthesis. DeepScan applies CoVe checkpoints to validate fluorescence PPB assays across Fanali (2011) and Vuignier (2010).

Try Doxa for Plasma Protein Binding Drug Development Research

Frequently Asked Questions

What is plasma protein binding in drug development?

PPB measures drug association with plasma proteins like HSA, affecting free fraction for distribution and clearance (Fasano et al., 2005).

What are main methods for PPB assessment?

Techniques include equilibrium dialysis, ultrafiltration, and crystallography for site mapping; analytical tools reviewed by Vuignier et al. (2010).

What are key papers on HSA ligand binding?

Fanali et al. (2011, 1817 citations) covers clinical aspects; Fasano et al. (2005, 1051 citations) details ligand properties; Petitpas et al. (2001) analyzes warfarin binding.

What are open problems in PPB research?

Challenges include in vivo corona prediction (Bertrand et al., 2017) and high-throughput affinity modeling beyond static structures (Kragh-Hansen et al., 2002).